Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

Summary: Patients with EGFR mutations exhibit immunosuppressive microenvironments, limiting responsiveness to immunotherapy. We used digital spatial profiling to analyze non-small cell lung carcinomas in 25 patients before and after EGFR tyrosine kinase inhibitor (TKI) treatment, including 14 patien...

Full description

Saved in:

Bibliographic Details
Main Authors:	Soomin Kim, Jaemoon Koh, Tae Min Kim, Songji Oh, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	iScience
Subjects:	therapeutics microenvironment immune response cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004224029638
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor
by: Krishna Babu Duggirala, et al.
Published: (2025-07-01)

Rational computational Design of new-Generation EGFR tyrosine kinase (EGFR-TK) inhibitors
by: Chandraprakash Gond, et al.
Published: (2025-05-01)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
by: Bhumsuk Keam, et al.
Published: (2020-10-01)

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
by: Defeng Hu, et al.
Published: (2025-04-01)

RETRACTED: De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report
by: Fei Gao, et al.
Published: (2019-02-01)

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
by: Nazia Chaudhary, et al.
Published: (2025-02-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
by: Yueyang Wang, et al.
Published: (2025-08-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
by: Kousuke Watanabe, et al.
Published: (2020-01-01)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
by: Masaki Kanazu, et al.
Published: (2021-01-01)

A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
by: Jianqiong Yin, et al.
Published: (2025-03-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

Computational design of binding proteins to EGFR domain II.
by: Yoon Sup Choi, et al.
Published: (2014-01-01)

Secondary metabolites of Trichoderma spp. as EGFR tyrosine kinase inhibitors: Evaluation of anticancer efficacy through computational approach.
by: H G Gowtham, et al.
Published: (2024-01-01)

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
by: Qi-An Wang, et al.
Published: (2025-03-01)

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach
by: Md Ali Asif Noor, et al.
Published: (2024-08-01)

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
by: Yaxiong Zhang, et al.
Published: (2025-07-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
by: Elena Ortiz-Zapater, et al.
Published: (2017-01-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
by: Chunyan Wang, et al.
Published: (2025-07-01)

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
by: Chang X, et al.
Published: (2025-03-01)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024-04-01)

KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer
by: Jae-Sun Choi, et al.
Published: (2025-01-01)

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer
by: Jianhua Zhan, et al.
Published: (2025-06-01)

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2025-05-01)

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
by: Chih-Yen Tu, et al.
Published: (2024-01-01)

Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
by: Zhixin Chen, et al.
Published: (2025-12-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
by: Lucia Regales, et al.
Published: (2007-08-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-Small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance
by: Aayush Rastogi, et al.
Published: (2025-07-01)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma
by: Mojtaba Sadeghi, et al.
Published: (2024-12-01)